

## Antisense Cancer Therapy: Do Antisense Oligonucleotides Hold Promise as a Cure for Cancer?

Mohammad Innus\*

Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, United States of America

Cancer is a dreadful disease causing a major percentage of deaths all over the world. Cancer is the second leading cause of death in the United States, trailing cardiovascular disease. According to National Cancer Institute statistics, over half a million deaths and a million and half new cases are predicted in the year 2017 [1]. The human body is composed of trillions of cells, and they perform specific functions with the aid of proteins. Genes impact the production of these proteins, and an error contained in these genes can yield aberrant versions of these proteins. In some cases, this can result in cancer. A newly diagnosed patient is often concerned for the following reasons: 1) they are afraid of cancer treatments being costly, 2) cancer survival rates are sometimes low and chances of reoccurrence of some cancers are high, and 3) the false paradigm that cancer is incurable.

Until modern times, cancer diagnosis and treatment exhibited very low success rates. Over the centuries, our understanding of cancer improved and new strategies for combatting cancer were created. Certain types of cancers are fully treatable and others could be prevented if diagnosed at the early stage. Despite tremendous efforts by researchers, fighting cancer is very challenging because there is an enormous similarity between diseased cells and healthy cells. Detection is the first step to defeat cancer. Fortunately, modern advancements in medicine provide ways to perform early stage diagnosis of cancer. For example, imaging tests, mammography, cytology, biopsy, and Pap smears [2]. The importance of early diagnosis of cancer relies in the virtue of cancer. Unlike other diseases, cancer invades its surrounding environment and spreads to other parts of the body. This is known as metastasis, which compounds the difficulty in treatment. Several techniques (invasive & non-invasive) are used to image cancer, but commonly used techniques are MRI and PET scan, but these techniques are expensive and not ideal for routine checkups. Relentless efforts in biomedical research have improved the effectiveness of non-invasive imaging techniques and made them cost effective. Several groups have been working on fluorescence imaging techniques in biomedical sciences to design effective and cheap strategies to image cancer. Innus Mohammad and co-workers developed a strategy to image hypoxic regions in tumor cells utilizing Indocyanine Green bis-acid [3]. Several other groups are working in this area to improve the effectiveness of non-invasive detection of cancer at early stage [4-7]. After the detection, doctors suggest the appropriate treatment procedures to patients. The most common treatments for cancer are a) surgery, b) chemotherapy, c) radiation therapy, and d) targeted therapy.

Surgery is frequently used to diagnose and treat breast cancer, but surgical treatments have side effects such as pain, infection, loss of organ function, bleeding, and blood clots. Some tumors are difficult to access during the surgery and can't be removed completely. The remaining tumorous tissue has a greater risk of tumor regrowth. As an alternative to surgery, chemotherapy drugs are developed based on the idea of targeting cell division of rapidly growing cells. Unfortunately, there are other cells that grow rapidly in our body including: hair, gastrointestinal epithelia and bone marrow. As a result, patients undergoing chemotherapy experience hair loss and gastrointestinal problems. In radiation therapy, tumors are exposed to high energy radiation to kill cancer cells. Although the current advanced techniques

minimize the effect of radiation on healthy cells, it has several side effects depending on the location of the tumor, such as skin problems, breathing problems, and sometimes the risk of developing a secondary cancer. The combination of these above mentioned therapies increase cancer survival rates, but side effects are still perilous.

New therapeutic strategies/models are necessary to reduce or eliminate toxic side effects. New advancements in cell biology, availability of human genome sequences and recent developments in oligonucleotide synthesis has opened the door for a targeted therapy called "antisense therapy". The first experimental evidence for antisense therapy was provided by Paul C. Zamecnik in 1978 [8]. In antisense therapy a single stranded oligonucleotide (DNA or RNA), which is a complimentary sequence of gene responsible for disease, is introduced into the cells to selectively turn the gene off. Antisense oligonucleotides are chemically modified or unmodified single stranded DNA/RNA molecules. Upon introduction, it is expected that complimentary oligos hybridize with the sequence of target mRNA and prevent further translation and protein synthesis. Three different approaches are adapted by the researchers to block the translation of mRNA, 1) antisense oligonucleotides, 2) ribozymes, and 3) short interfering RNA (siRNA). Ribozymes are RNA molecules with catalytic activity. When these molecules bind target mRNA, the phosphodiester backbone gets cleaved and the mRNA becomes deactivated. Short interfering RNA (siRNA) is a double stranded synthetic RNA that is designed to silence the particular gene by mRNA degradation. The goal of all these molecules is to hijack protein synthesis at the level of translation to cure genetic disorders.

Although the idea behind antisense oligonucleotide therapy sounds extraordinarily simple, there are several challenges associated with this approach (Figure 1). Despite two decades of extensive research, only two RNA therapeutic drugs were approved by FDA, Fomivirsen and Kynamro. The main hurdle that slowed the progress of antisense drugs is lack of methods to design endonuclease stable oligonucleotides and delivering them efficiently into the cells. Due to lack of efficacy and immune reactions to the treatments, early attempts to introduce naked oligonucleotides experienced a setback. As a result of recent improvements in oligonucleotide deliveries for antisense therapy (for example, N-Acetylgalactosamine conjugate and nanoparticle-based approaches), more and more companies are actively taking part in

\*Corresponding author: Mohammad Innus, Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, 364 Plantation Street, Worcester, Massachusetts 01605, United States of America, Tel: 5088562526; E-mail: [Innus.Mohammad@umassmed.edu](mailto:Innus.Mohammad@umassmed.edu)

Received May 25, 2017; Accepted May 27, 2017; Published June 12, 2017

Citation: Innus M (2017) Antisense Cancer Therapy: Do Antisense Oligonucleotides Hold Promise as a Cure for Cancer?. Chem Sci J 8: e117. doi: [10.4172/2150-3494.1000e117](https://doi.org/10.4172/2150-3494.1000e117)

Copyright: © 2017 Innus M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Figure 1: Cartoon representation of the antisense oligonucleotide therapy mechanism.

antisense therapeutic research [9-22]. Currently, over a hundred oligonucleotides are in clinical trials from 30 different pharmaceutical companies [23]. The resurgence of antisense therapy looks promising, with key players in the field are anticipating drugs to hit the market very soon.

Along with working towards better strategies to defeat cancer, I believe that informational sessions for cancer patients to create hope is also very important. As mentioned earlier, creating awareness about the modern advancements in the medical field and the availability of new classes of treatments helps to allay patients' fear. There is a quote by Sun Tzu: "Victorious warriors win first and then go to war, while defeated warriors go to war first and then seek to win." Helping a patient understand their options and how treatment is often successful can improve patient outlook and tolerance of treatments.

## References

1. <https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html>
2. <http://www.who.int/cancer/detection/en/>
3. Zhou F, Zanganeh S, Mohammad I, Dietz C, Abuteen A, et al. (2015) Targeting tumor hypoxia: a third generation 2-nitroimidazole-indocyanine dye-conjugate with improved fluorescent yield. *Organic & Biomolecular Chemistry* 13: 11220-11227.
4. Duong T, Li X, Yang B, Schumann C, Albarqi HA, et al. (2017) Phototheranostic nanoplatform based on a single cyanine dye for image-guided combinatorial phototherapy. *Nanomedicine: Nanotechnology, Biology, and Medicine* 13: 955-963.
5. Ma R, Wu Q, Si T, Chang S, Xu RX (2017) Oxygen and Indocyanine Green loaded microparticles for dual-mode imaging and sonodynamic treatment of cancer cells. *Ultrasonics Sonochemistry* 39: 197-207.
6. Sano K, Ohashi M, Kanazaki K, Makino A, Ding N, et al. (2017) Indocyanine Green-Labeled Polysarcosine for in Vivo Photoacoustic Tumor Imaging. *Bioconjugate Chemistry* 28: 1024-1030.
7. Song S, Shen H, Yang T, Wang L, Fu H, et al. (2017) Indocyanine Green Loaded Magnetic Carbon Nanoparticles for Near Infrared Fluorescence/Magnetic Resonance Dual-Modal Imaging and Photothermal Therapy of Tumor. *Applied Materials and Interfaces* 9: 9484-9495.
8. <http://lemelson.mit.edu/resources/paul-c-zamecnik>
9. Casaca-Carreira J, Temel Y, Larrakoetxea I, Jahanshahi A (2017) Distribution and Penetration of Intracerebroventricularly Administered 2'OMePS Oligonucleotide in the Mouse Brain. *Nucleic Acid Therapeutics* 27: 4-10.
10. Collin RWJ, Garanto A (2017) Applications of antisense oligonucleotides for the treatment of inherited retinal diseases. *Current Opinion in Ophthalmology* 28: 260-266.
11. Delie F, Berton M, Allémann E, Gurny R (2001) Comparison of two methods of encapsulation of an oligonucleotide into poly(D,L-lactic acid) particles. *International Journal of Pharmaceutics* 214: 25-30.
12. DeLong RK, Akhtar U, Sallee M, Parker B, Barber S, et al. (2009) Characterization and performance of nucleic acid nanoparticles combined with protamine and gold. *Biomaterials* 30: 6451-6459.
13. Gill B, Singh J, Sharma V, Hari KS (2012) Emulsomes: An emerging vesicular drug delivery system. *Asian Journal of Pharmaceutics* 6: 87-94.
14. Gonzalez FM, Tillman L, Hardee G, Bodmeier R (2002) Characterization of alginate/poly-L-lysine particles as antisense oligonucleotide carriers. *International Journal of Pharmaceutics* 239: 47-59.
15. Janas MM, Jiang Y, Schlegel MK, Waldron S, Kuchimanchi S, et al. (2017) Impact of Oligonucleotide Structure, Chemistry, and Delivery Method on *In Vitro* Cytotoxicity. *Nucleic Acid Therapeutics* 27: 11-22.
16. Jarver P, Langel U (2006) Cell-penetrating peptides - A brief introduction. *Biochimica et Biophysica Acta - Biomembranes* 1758: 260-263.
17. Jeong JH, Kim SH, Kim SW, Park TG (2006) Intracellular delivery of poly(ethylene glycol) conjugated antisense oligonucleotide using cationic lipids by formation of self-assembled polyelectrolyte complex micelles. *Journal of Nanoscience and Nanotechnology* 6: 2790-2795.
18. Lee T, Awano H, Yagi M, Matsumoto M, Watanabe N, et al. (2017) 2'-O-methyl RNA/ethylene-bridged nucleic acid chimera antisense oligonucleotides to induce dystrophin exon 45 skipping. *Genes* 8: 67.
19. Schmidt K, Prakash TP, Donner AJ, Kinberger GA, Gaus HJ (2017) Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor. *Nucleic Acids Research* 45: 2294-2306.
20. Sprangers AJ, Hao L, Banga RJ, Mirkin CA (2017) Liposomal Spherical Nucleic Acids for Regulating Long Noncoding RNAs in the Nucleus. *Small* 13: 10.
21. Yamada Y, Tabata M, Yasuzaki Y, Nomura M, Shibata A, et al. (2014) A nanocarrier system for the delivery of nucleic acids targeted to a pancreatic beta cell line. *Biomaterials* 35: 6430-6438.
22. Zimmer A (1999) Antisense oligonucleotide delivery with polyhexylcyanoacrylate nanoparticles as carriers. *Methods: A Companion to Methods in Enzymology* 18: 286-295.
23. <http://ma.dk/2013/ma-antisense-drugs-in-the-pipelines/>